Backs FY25 adjusted EBITDA view $55M-$58M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on NEO: Is NEO a Buy, Before Earnings? PacBio appoints Smith to board of directors NeoGenomics Announces Executive Bonuses and Revenue Growth NeoGenomics sees FY25 revenue $735M-$745M, consensus $727.9M NeoGenomics updates long-term financial plan
